Oncology and immunology are converging in powerful ways, as researchers uncover the immune system’s role in tumor progression, response to therapy, and adverse events.
Whether profiling cytokines, monitoring response to immunotherapy or identifying markers of toxicity, NULIS assays offer ultra-sensitive multiplexed assays that enable researchers to detect and quantify critical biomarkers in clinical cohorts.
Protein biomarkers enable early cancer detection, often before symptoms appear, improving the chances of successful treatment
Biomarker profiling helps tailor treatment strategies to individual patients based on their specific cancer type and protein expression patterns.
Protein biomarkers can track cancer progression and response to therapy, allowing for timely adjustments in treatment plans.
Immuno-profiling has identified early signatures associated with several adverse immune reactions to IO therapy.
Many protein biomarkers can be detected in blood, urine, or other body fluids, reducing the need for invasive biopsies.
Comprehensive analysis of health and disease
High sensitivity measurement of validated biomarkers
Jamie S. Lin, MD
Niyati Jhaveri, PhD
Hussein Abbas, PhD
Alex Forrest-Hay
Steve Williams, MD, PhD
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.
